Supplementary Figure 2 from Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

PDF file - 71KB, VPC of the biomarker model in colo-205 xenograft bearing mice following a single 3.125, 6.25 or 12.5 mg/kg oral dose of LY2835219.